XS
NBRV

XR Securities’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

XR Securities’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-423
Closed -$6K – 569
2021
Q4 		$6K Buy
+423
New +$10K ﹤0.01% 417

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XR Securities's NBRV Position: Q1 2022 in Review

XR Securities sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2022, closing a stake of 423 shares — an estimated $6K sold.

XR Securities first reported a position in NBRV in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 29 funds tracked by Wall St. Rank hold NBRV as of Q1 2022.

  • XR Securities reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2022 after selling out during the quarter.
  • XR Securities sold 423 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2022, an estimated $6K.
  • XR Securities first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2021 and held it in 1 quarter.
  • XR Securities's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $6K in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2022.

Based on XR Securities's 13F filing for Q1 2022, filed 14 Apr 2022.